Financial Performance - The company's operating revenue for Q1 2024 reached ¥805,896,093.75, representing a year-on-year increase of 20.34%[3] - The net profit attributable to shareholders was ¥54,711,195.13, with a significant increase in net profit excluding non-recurring gains and losses to ¥26,087,497.49, up 1,461.09%[3] - Net profit for Q1 2024 was ¥52,079,837.67, compared to a net loss of ¥29,006,693.77 in Q1 2023, marking a significant turnaround[53] - The company reported a total comprehensive income of ¥17,836,635.12 in Q1 2024, compared to a loss of ¥61,491,525.83 in Q1 2023[53] - The company achieved a profit before tax of ¥58,739,584.75 in Q1 2024, a significant improvement from a loss of ¥31,596,670.73 in Q1 2023[53] Cash Flow and Operating Activities - The net cash flow from operating activities decreased by 53.79% to ¥35,861,697.83[3] - Cash flow from operating activities for Q1 2024 was ¥35,861,697.83, down from ¥77,608,123.07 in Q1 2023[56] - The company's cash flow from operating activities was impacted by the scale expansion of its procurement business[18] - The company reported a net increase in cash and cash equivalents of approximately $164.17 million, compared to a decrease of $121.92 million in the previous year[38] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,696,236,079.64, a slight increase of 0.26% compared to the end of the previous year[3] - Current assets increased to approximately $6.93 billion as of March 31, 2024, compared to $6.77 billion at the end of 2023, reflecting a growth of about 2.43%[29] - Total non-current assets decreased to approximately $4.76 billion from $4.90 billion, a decline of about 2.66%[31] - Total liabilities increased slightly to approximately $3.40 billion from $3.39 billion, reflecting a growth of about 0.05%[33] - The company's total equity rose to approximately $8.30 billion from $8.28 billion, indicating an increase of about 0.11%[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 119,454[7] - The largest shareholder, Guangxi Investment Group Co., Ltd., holds 24.90% of the shares[7] - Shareholders' equity attributable to the parent company was ¥6,591,643,953.71, reflecting a 0.34% increase from the previous year[3] Earnings and Expenses - The weighted average return on equity increased by 1.09 percentage points to 0.83%[3] - Basic earnings per share for Q1 2024 were ¥0.0160, compared to a loss of ¥0.0050 per share in Q1 2023[53] - Research and development expenses for Q1 2024 were ¥25,925,300.81, slightly up from ¥25,174,529.19 in Q1 2023[50] - Sales expenses decreased to ¥209,029,038.08 in Q1 2024 from ¥333,350,800.02 in Q1 2023, a reduction of 37.3%[50] - Other income increased to ¥26,347,218.11 in Q1 2024 from ¥13,869,037.33 in Q1 2023, reflecting a growth of 89.8%[50] Asset Transactions - The company successfully transferred assets for ¥130,269,731.33, receiving the full payment by the reporting date[10] - The company plans to transfer an 18% stake in a subsidiary for no less than ¥194,112,400.00, with the transaction pending regulatory approval[10] Non-Recurring Gains and Losses - The company's non-recurring gains and losses totaled RMB 28,623,697.64 after tax and minority interest adjustments[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 1,461.09% due to a reduction in company period expenses[18]

证券代码：600252 证券简称：中恒集团 公告编号：临 2024-31 广西梧州中恒集团股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）于 2024 年 3 月 8 日和 2024 年 3 月 28 日分别召开第十届董事会第十二次会议和 2024 年第二 次临时股东大会，会议审议通过了《中恒集团关于以集中竞价交易方式回购股份 的议案》，同意公司以自有资金，以不超过 3.34 元/股回购公司部分社会公众股份， 用于实施股权激励，未实施股权激励部分将依法予以注销。回购资金总额为不低 于人民币 15,000.00 万元（含）且不超过人民币 20,000.00 万元（含）。回购期限为 自 2024 年 3 月 28 日召开的股东大会审议通过回购方案之日起不超过 6 个月。具 体内容详见公司于 2024 年 3 月 29 日在上海证券交易所网站披露的《中恒集团关 于以集中竞价交易方式回购股份的回购报告书》（公告编号：临 2024-18）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2024-30 特此公告。 （以下无正文） 1 广西梧州中恒集团股份有限公司 关于公司董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024 年 4 月 9 日，广西梧州中恒集团股份有限公司（以下简称"公司"或 "中恒集团"）董事会收到公司董事李林先生提交的书面辞职信。李林先生因工 作变动原因申请辞去公司第十届董事会董事及董事会下设专门委员会委员职务， 辞去上述职务后，其不再担任公司其他任何职务。 根据《公司法》《公司章程》及有关法律法规的规定，李林先生的辞职未导 致公司董事会成员低于法定最低人数，其辞任不会影响公司及董事会正常运作， 李林先生的辞职自送达董事会之日起生效。公司董事会将按照相关法定程序，尽 快完成董事的补选工作。 截至目前，李林先生持有公司 2021 年限制性股票激励获授的股份 536,000 股，持股比例占公司目前总股本的 0.0155%。李林先生辞职后，不再具备激励对 象的资格，公司将按照《中恒集团 2021 年限制性股票激励计划（ ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2024-29 广西梧州中恒集团股份有限公司 关于公开挂牌转让参股公司股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）将所 持广西联合资产管理股份有限公司（以下简称"联合资管"）的 18%股权通过北 部湾产权交易中心公开挂牌转让。竞买人广西宏桂资本运营集团有限公司（以下 简称"广西宏桂集团"）以 194,112,400.00 元成交。 ●本次交易不构成关联交易，亦不构成重大资产重组，不存在重大法律障碍。 二、交易进展 2023 年 9 月 13 日，公司在北部湾产权交易中心公开挂牌转让上述股权， 挂牌价格为 19,411.24 万元。 1 2024 年 3 月 29 日，在挂牌期满后，公司收到北部湾产权交易中心出具的 《电子竞价成交确认书》，竞买人广西宏桂集团以 194,112,400.00 元成交。同日， 公司与受让方广西宏桂集团签署了《广西联合资产管理股份有限公司股份转让 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2024-28 广西梧州中恒集团股份有限公司 关于为控股子公司广西中恒中药材产业发展有限公司 提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ●被担保人名称及是否为关联担保：广西中恒中药材产业发展有限公司（以 下简称"中恒中药材"）为广西梧州中恒集团股份有限公司（以下简称"公司"或"中 恒集团"）的控股子公司。本次担保不涉及关联担保。 ●本次担保金额及已实际为其提供的担保余额：公司本次为中恒中药材提供 的担保金额最高额为人民币 9,999,852 元；截至本公告披露日，公司为中恒中药 材实际提供的担保余额为人民币 19,999,704 元（含本次）。 公司分别于 2023 年 3 月 27 日、5 月 8 日召开中恒集团第九届董事会第五 ●本次担保是否有反担保：否 ●对外担保逾期的累计数量：无 一、担保情况概述 （一）担保基本情况 为满足控股子公司中恒中药材日常经营和业务发展需求，保证中恒中药材 生产经营活动的顺利开展，公司为中恒中药材向金融机构申请融资 ...

广西梧州中恒集团股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600252 证券简称：中恒集团 公告编号：临 2024-27 （以下无正文） （此页无正文，仅为《广西梧州中恒集团股份有限公司关于以集中竞价交易方式 回购股份的进展公告》盖章页） | 重要内容提示： | | --- | | 回购方案首次披露日 | 2024/3/11 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2024 3 | 28 | 日~2024 | 年 9 | 月 | 27 | 日 | | 预计回购金额 | 15,000.00 | | 万元~20,000.00 | 万元 | | | | | 回购用途 | 用于股权激励 | | | | | | | | 累计已回购股数 | 0 万股 | | | | | | | | 累计已回购股数占总股本比例 | 0% | | | | | | | ...

Financial Performance - The company's operating revenue for 2023 reached ¥3,096,542,053.05, representing a 14.10% increase compared to ¥2,713,769,838.72 in 2022[21] - Net profit attributable to shareholders was ¥84,308,789.04, a 6.69% increase from ¥79,025,459.61 in the previous year[21] - The net profit after deducting non-recurring gains and losses surged by 321.59% to ¥22,729,645.54 from ¥5,391,356.31 in 2022[21] - Cash flow from operating activities improved significantly to ¥403,025,145.87, compared to a negative cash flow of ¥170,090,446.75 in 2022[21] - Total assets as of the end of 2023 were ¥11,665,960,096.15, a decrease of 0.75% from ¥11,754,668,906.80 at the end of 2022[21] - The net assets attributable to shareholders increased slightly by 0.79% to ¥6,569,449,409.17 from ¥6,517,784,301.82 in 2022[21] - Basic earnings per share for 2023 increased by 6.49% to CNY 0.0246 compared to CNY 0.0231 in 2022[23] - The weighted average return on equity rose to 1.27% in 2023, up from 1.19% in 2022, an increase of 0.08 percentage points[24] Operational Highlights - There were no significant operational risks reported that could impact the company's performance during the reporting period[10] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[9] - The financial report received a standard unqualified audit opinion from Yongtuo Accounting Firm[6] - The company is focusing on refined operations and stable sales teams to enhance sales volume and gross profit in the cardiovascular medication sector[24] - The company optimized its sales structure by establishing eight major battle zones and two sales networks to enhance market coverage[33] - The company has strengthened its international standard certifications, achieving stable product quality and service quality during the reporting period[36] Research and Development - The company has 18 provincial and ministerial-level innovation platforms, including 2 national recognized enterprise technology centers and 1 postdoctoral research station[37] - The company’s R&D collaboration with Shanghai University of Traditional Chinese Medicine focuses on the development of new Chinese medicine products and technology transfer[37] - The company has 129 effective patents, including 102 invention patents, showcasing its strong R&D capabilities[45] - The total R&D investment amounted to CNY 167,415,987.69, representing 5.41% of the operating revenue, with capitalized R&D accounting for 8.18% of the total[82] - The company has established 14 key research and development platforms to enhance its overall R&D capabilities and core competitiveness[59] Market Expansion and Strategy - The company aims to expand its market share by enhancing online user operations and increasing the density of domestic regional layouts[34] - The company plans to expand its pharmaceutical export trade, focusing on markets in Hong Kong, Macau, and Taiwan, to enhance its market presence[72] - The company is focusing on compliance with market regulations to enhance competitive practices and transparency in operations[99] - The company is actively adjusting its investment strategies in line with national health development policies, particularly in digital health technologies[100] - The company is exploring potential acquisitions to enhance its product portfolio, targeting a deal valued at approximately 500 million CNY[170] Corporate Governance and Management - The company has established a comprehensive salary management system that aligns with industry practices and regulatory requirements[180] - The company has a performance evaluation system for senior management based on operational performance indicators, which influences the distribution of performance bonuses[180] - The company is focusing on enhancing its market position through strategic executive changes and stock repurchase programs[169] - The company held 5 shareholder meetings, 16 board meetings, and 9 supervisory meetings during the reporting period, ensuring compliance with legal and regulatory requirements[163] - The company has implemented measures to ensure the independence of its assets, personnel, and operations[163] Product Development and Innovation - The company is focusing on the development of new products and technologies to diversify its offerings and enhance market competitiveness[157] - The company is actively developing new products, including the injection of thrombolytic agents and various traditional Chinese medicine formulations, with several projects in different stages of research and approval[112] - The company has introduced new products continuously and accelerated the market entry of already introduced new products[54] - The company is investing 200 million CNY in R&D for new technologies aimed at enhancing product efficiency[170] - The company plans to develop a comprehensive investment system covering the entire life cycle and industry chain in the health sector[131] Financial Management and Investments - The company has made a significant increase in external equity investments, totaling 715.41 million RMB in 2023, compared to only 0.25 million RMB in the previous year[127] - The company is actively seeking quality investment targets to expand its business and enhance its strategic positioning in the health sector[127] - The company plans to apply for credit guarantees from financial institutions for its 2023 annual comprehensive credit limit[183] - The company has a structured training program that includes both online and offline methods, focusing on various professional fields[197] - The company emphasizes a cash dividend policy, aiming for a minimum of 20% of the distributable profit to be allocated as cash dividends[198]

广西梧州中恒集团股份有限公司 内部控制审计报告 永证专字[2024]第 310060 号 永拓会计师事务所（特殊普通合伙） 内部控制审计报告 永证专字（2024）第 310060 号 广西梧州中恒集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了广 西梧州中恒集团股份有限公司（以下简称中恒集团）2023 年 12 月 31 日的财务报告内部控 制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定，建立健全和有效实施内部控制，并评价其有效性是企业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见， 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，中恒集团按照 ...

2023 年度，广西梧州中恒集团股份有限公司（以下简称"公司" 或"中恒集团"）董事会审计委员会根据《上市公司治理准则》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》《公司章 程》《董事会审计委员会议事规则》的规定，勤勉尽责，认真履行审 计监督职责。现将董事会审计委员会 2023 年度的履职情况汇报如下： 一、审计委员会基本情况 公司第九届董事会审计委员会由四名董事组成，分别为独立董 事李中军先生、王洪亮先生、李俊华先生和非独立董事莫宏胜先生， 主任委员由具有会计专业人士资格的独立董事李俊华先生担任。 2023 年 10 月，公司通过选举产生了第十届董事会审计委员会成 员，审计委员会由五名董事组成，分别为独立董事陈道峰先生、龚 行楚先生、李俊华先生和非独立董事王海润先生、徐诗玥女士，主 任委员由具有会计专业人士资格的独立董事李俊华先生担任。 二、审计委员会会议召开情况 2023 年度，公司董事会审计委员会共召开 6 次会议，审议通过 了 15 项议案事项，具体情况如下： 广西梧州中恒集团股份有限公司 董事会审计委员会 2023 年度履职情况报告 | 会议名称 | 会议召开时间 | | | | ...

广西梧州中恒集团股份有限公司 2023 年度独立董事述职报告 （王洪亮） 本人王洪亮，作为广西梧州中恒集团股份有限公司（以下简称"公 司"或"中恒集团"）第九届董事会独立董事，2023 年，在本年度任职 期间内（本年度任职期间：2023 年 1 月 1 日至 2023 年 9 月 27 日）， 本人严格按照《公司法》《上市公司治理准则》《上海证券交易所 上市公司自律监管指引第 1 号——规范运作》等有关法律法规及《公 司章程》的规定和要求，独立、客观地行使独立董事职权，忠实、 勤勉地履行职责，切实维护了公司的整体利益和中小股东的合法利 益。现将本人履职情况汇报如下： 一、基本情况 二、独立董事年度履职概况 （一）出席董事会及股东大会情况 2023 年 9 月 27 日，公司完成第十届董事会换届选举工作，会议 选举产生新任独立董事，本人不再担任公司独立董事及董事会各专 门委员会中相关职务。 （一）独立董事简介 王洪亮先生，男，1973年4月出生，中共党员，清华大学法学院， 长聘教授，博士生导师。兼任内蒙古第一机械集团股份有限公司、 大连银行股份有限公司等企业独立董事，北京仲裁委员会仲裁员， 中国国际经济贸易仲裁 ...